The COVID-19 pandemic put a spotlight on how the bio/pharmaceutical industry and regulators can work together to bring life-saving therapies to the market fast to safeguard and improve public health. The lessons learned […]
Resources
Article
The most effective contract development and manufacturing organizations (CDMOs) help their clients by developing optimal, cost-efficient processes. Since its origins over 50 years ago, BIOVECTRA has […]
Article
Certificates of analysis (CoAs) are used by materials suppliers to identify the product they are providing to a pharmaceutical manufacturer. They include information such as product name, material grade, batch number, expiration dates, testing dates, information on analytical […]
Article
Microbial fermentation has its place in the biomanufacturing industry, despite the prevalence of mammalian-based cell culture processes for the production of biologics. However, despite the lower costs and potential for substantial product […]
Article
Perhaps the biggest supply issue for cell and gene therapies is a lack of reliable sources of GMP-grade plasmid DNA. The supply of pDNA – and, therefore, mRNA – is constrained by both manufacturing issues and short supply of consumables […]
Article
Two decades ago, the Canadian CDMO BioVectra installed Heather Delage as its director of business development. She was named vice president of business development […]
Article
Effective and safe APIs provide the necessary element of drugs to treat patients with a variety of health conditions. It is, therefore, crucial that the quality of APIs, along with other ingredients that make up a medicine […]
Article
Founded in 1970, BIOVECTRA is a CDMO with specialties in microbial fermentation, complex chemistry and biologics. The company is looking to bolster its mRNA manufacturing capability.[…]
Article
Headquartered in Atlantic Canada, BIOVECTRA is a heavyweight global CDMO with a rich history and relentless focus on adapting to future trends. With an eye on the next generation of pharmaceuticals […]
Interview
When Dr. Marc Sauer joined BIOVECTRA as a research scientist in 2006, the company of 60 was focused on small molecules and microbial fermentation. Today, at just shy of 600 employees, BIOVECTRA is a […]
Interview
The location of a CDMO is always an important consideration by any sponsor organization considering its manufacturing strategy. BIOVECTRA’s facilities are located across several […]
Article
BIOVECTRA today announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada. This exciting new capability will result from […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.